CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 595 enrolled
Drug / intervention
Paclitaxel +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02264990
NCT02264990Phase 3Completed
CompareCT.gov

A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers

AbbVie·interventional·Posted Oct 15, 2014·Updated Feb 26, 2021

In Brief

A Phase 3 clinical trial evaluating Paclitaxel, Carboplatin, and 3 other interventions for Non-squamous Non-small Cell Lung Cancer. Completed, enrolled 595 participants across 140 sites in 20 countries.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-squamous Non-small Cell Lung Cancer
CountriesArgentina, Australia, Canada, Czechia, Denmark, Finland, Germany, Hungary, Israel, Japan, Netherlands, New Zealand, Russia, South Africa, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 15, 2014
Enrollment StartSep 30, 2014
Primary CompletionNov 14, 2019
Study CompletionFeb 21, 2020
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 11.7 years ago

Interventions

Paclitaxeldrug

Administered by Intravenous infusion on Day 1 of each 21-day cycle

Carboplatindrug

Administered by Intravenous infusion on Day 1 of each 21-day cycle

Cisplatindrug

Administered by Intravenous infusion on Day 1 of each 21-day cycle

Veliparibdrug

Oral capsule, administered twice daily for 7 days in each 21-day cycle

Pemetrexeddrug

Administered by Intravenous infusion on Day 1 of each 21-day cycle